Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,522 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03926338RecruitingPhase 2
Before-surgery immunotherapy for MSI-H or dMMR colon cancer
This trial studies a treatment given before surgery using toripalimab, with or without celecoxib, for colon or rectal cancer that has MSI-H or dMMR tumor features. It aims to shrink or control the cancer before the operation and compare whether adding celecoxib helps.
Guangzhou, GuangdongAges 18–75 - NCT05964387Recruiting
Silver fluoride treatment and local numbing for tooth cavities
This study tests whether applying silver diamine fluoride (a cavity-stopping liquid) changes how well local numbing works during dental treatment for certain tooth defects. It may help determine the safest and most comfortable way to treat weak, cavity-prone molars in children.
Ann Arbor, MichiganAges 6–11 - NCT05944224RecruitingPhase 1/Phase 2
SPH4336 for advanced solid tumors with or without immunotherapy
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Fuzhou, FujianAges 18–75 - NCT05954312RecruitingPhase 1
Study of an experimental drug for advanced solid tumors
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Jacksonville, FloridaAges 18 years+ - NCT05918302RecruitingPhase 3
Compare radiotherapy versus everolimus for lung and thymus tumors
This study compares two treatment options for somatostatin receptor–positive neuroendocrine tumors from the lung or thymus: radiotherapy versus everolimus. It aims to see which treatment works better and how safe each option is for people whose disease has progressed within the last year.
Edegem, EdegemAges 18 years+ - NCT05878314Recruiting
Testing how hormones and tumor markers guide breast cancer treatment
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
TübingenAges 18 years+ - NCT05884255RecruitingPhase 3
Lutetium brain-sparing therapy for advanced gut and pancreas tumors
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05886920RecruitingPhase 1/Phase 2
Study drug for advanced cancers with specific MAPK changes
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
Detroit, MichiganAges 18 years+ - NCT05547321RecruitingPhase 1
New cancer drug plus immunotherapy for advanced solid tumors
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Boston, MassachusettsAges 18 years+ - NCT05872347RecruitingPhase 2
Brain metastasis breast cancer trial with hormone therapy plus SPH4336
This trial tests whether SPH4336, added to standard hormone (endocrine) therapy, can improve outcomes for people with breast cancer that has spread to the brain. It also looks closely at safety and side effects.
Hefei, AnhuiAges 18–75 - NCT05790213RecruitingPhase 2
Hormone therapy plus targeted prostate treatment for intermediate cancer
This Phase 2 study tests whether combining hormone treatment (androgen deprivation therapy) with focal ablation (targeted destruction of prostate tissue) controls intermediate-risk prostate cancer. It may help some men avoid or reduce more aggressive treatment, while still aiming for cancer control.
Chicago, IllinoisAges 18 years+ - NCT05076682RecruitingPhase 2
Study for hard-to-treat triple-negative breast cancer that keeps growing
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
ShanghaiAges 18–70 - NCT05764720Recruiting
Personalized targeted radiation for borderline pancreatic cancer
This study tests a personalized form of stereotactic radiation therapy (high-precision radiation planned to fit your tumor) after you’ve had some chemotherapy. It aims to treat pancreatic tumors while limiting exposure to nearby healthy organs.
Birmingham, AlabamaAges 18 years+ - NCT05753618RecruitingPhase 4
Skipping growth-factor shots during breast cancer chemotherapy
This trial tests whether patients can safely skip a preventive white-blood-cell growth shot (G-CSF) while receiving a common breast cancer chemotherapy regimen. It may help reduce injections and side effects, while watching closely for fevers and low white blood counts.
Kingston, OntarioAges 18 years+ - NCT04204850RecruitingPhase 2
Cabozantinib for liver cancer that returns after liver transplant
This trial studies cabozantinib, a cancer medicine, for liver cancer that has come back after a liver transplant. It’s for people whose cancer can’t be cured with more surgery or local procedures, to see if the treatment can help control the disease.
Toronto, OntarioAges 18 years+ - NCT05720117RecruitingPhase 1
Study drug for advanced solid tumors with limited treatments left
This Phase 1 study tests PYX-201 in people with advanced (grown or spread) solid cancers to see if it is safe and how it works. You may qualify if your cancer has had up to a couple of prior treatments and you can safely take study medicines and undergo required testing like a tumor biopsy.
Scottsdale, ArizonaAges 18 years+ - NCT05727176RecruitingPhase 2
Futibatinib for advanced bile duct cancer with FGFR2 changes
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT05701527RecruitingPhase 1
EBC-129 for advanced solid tumors with limited treatment options
This Phase 1 study tests EBC-129, a new investigational treatment, in people with advanced solid tumors that cannot be fully removed and have limited or no good standard treatment options. The goal is to learn if the treatment is safe, find helpful dosing, and see signs it may slow the cancer.
Aurora, ColoradoAges 18 years+ - NCT05687682RecruitingPhase 1
AM-928 infusion safety study for advanced solid tumors
This Phase 1 trial tests how safe AM-928 is when given through an IV infusion to people with advanced solid cancers that can’t be removed by surgery and have stopped responding to standard treatments. It may help doctors learn the safest dose and whether the drug causes side effects worth watching.
TaipeiAges 18 years+ - NCT05683418RecruitingPhase 1
Study of a new drug for PIK3CA-mutated HR+ HER2- breast cancer
This early-stage study tests the safety and tolerability of TOS-358 in women with HR-positive, HER2-negative breast cancer that has a specific gene change (PIK3CA). It may help learn whether this targeted treatment is safe enough to move forward.
Chicago, IllinoisAges 18 years+ - NCT05684965RecruitingPhase 1/Phase 2
Study drug for advanced solid cancers after standard treatments
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
Sacramento, CaliforniaAges 18 years+ - NCT05674825RecruitingPhase 1/Phase 2
Personalized treatment using tumor test results for aggressive cancers
This early-phase study tests whether a personalized cancer treatment plan based on your tumor’s test results can help people with aggressive cancers that are hard to treat. It may be an option if standard treatments didn’t work, aren’t possible for you, or you have few treatment choices.
Milwaukee, WisconsinAges 18 years+ - NCT05704530Recruiting
Liquid blood tests for early esophageal cancer
This trial studies how well “liquid biopsy” blood tests can work in people with newly diagnosed, operable esophageal cancer. It may help doctors monitor the cancer and guide treatment planning alongside standard care.
AntwerpAges 18 years+ - NCT05599048RecruitingPhase 1/Phase 2
MRI scan using a special sugar to study solid tumors
This early-phase study tests whether a special MRI scan with injected labeled “pyruvate” can act as a biomarker (a measurable sign) for advanced solid tumor activity. It may help doctors see tumor metabolism over time and better track how treatment is affecting cancer.
San Francisco, CaliforniaAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,522 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.